Drugs / Immunoglobulin G
Immunoglobulin G
also known as
Human Immunoglobulin G · Ig NextGen 16% · IGIV · Immune Globulin Intravenous (Human) · IVIG-SN · Ⅳ-Globulin S inj.
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07025577 | Jun → Aug 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06834035 | Aug 2025 → Mar 2027 expected | acquired epidermolysis bullosa, recessive dystrophic epidermolysis bullosa | M. Peter Marinkovich | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04175522 | Nov 2019 → Jun 2020 | autoimmune encephalitis | Green Cross Corporation | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01315496 | Oct 2009 → Dec 2013 | infectious disease with sepsis | Green Cross Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT00680446 | Apr 2008 → May 2013 | immunodeficiency disease | CSL Limited | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04003844 | Feb → Nov 2019 | Kawasaki disease | Green Cross Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01524939 | Jan → Sep 2012 | Kawasaki disease | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunoglobulin G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04003844 ↗ |
| Known as | Human Immunoglobulin G | “Intravenous Administration of 'IV-Globulin S inj.(Human Immunoglobulin G)' as an Adjuvant Therapy in Adult Subjects with Community-Acquired Severe Sepsis or Septic Shock.” NCT01315496 ↗ |
| Known as | Ig NextGen 16% | “Immunoglobulin G (Ig NextGen 16%)” NCT00680446 ↗ |
| Known as | IGIV | “high-dose human Immunoglobulin G Intravenous (IGIV) 10% in subjects with Kawasaki diseases (KD).” NCT04003844 ↗ |
| Known as | Immune Globulin Intravenous (Human) | “The purpose of this study is to evaluate the safety, efficacy and of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with kawasaki diseases.” NCT01524939 ↗ |
| Known as | IVIG-SN | “The purpose of this study is to evaluate the safety, efficacy and of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with kawasaki diseases.” NCT01524939 ↗ |
| Known as | Ⅳ-Globulin S inj. | “This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.” NCT01315496 ↗ |
| Modality | Protein / enzyme biologic | “liquid immunoglobulin (antibody) preparation” NCT00680446 ↗ |
| Route | Subcutaneous | “Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G” NCT00680446 ↗ |